Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2019 | Lymphoma updates: CAR-T, brentuximab & nivolumab

Nathan Fowler • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Follicular Lymphoma Hodgkin Lymphoma Indolent B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Brentuximab vedotin CAR-T Checkpoint inhibitors JCAR017 Nivolumab

Nathan Fowler, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights key lymphoma news from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include updates on JCAR017 in non-Hodgkin lymphoma, and the combination of bretuximab vedotin and the checkpoint inhibitor nivolumab in Hodgkin lymphoma.

More from Nathan Fowler

ELARA: Tisa-cel in follicular lymphoma 1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
10 year follow up of rituximab and lenalidomide in low tumor burden FL 0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
RELEVANCE: Rituximab and lenalidomide in FL 1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
ELARA: tisa-cel in R/R follicular lymphoma 3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals